Diagnosis* | Baseline† | Treatment phase | Observational phase | |||
Polyps | Subjects‡ | Polyps | Subjects‡ | Polyps | Subjects‡ | |
n | n | n | n | n | n | |
Sessile serrated adenoma/polyp | 18 | 17 | 128 | 96 | 79 | 62 |
SSA/P with cytological dysplasia | 12 | 11 | 4 | 4 | 3 | 3 |
Traditional serrated adenoma | 1 | 1 | 8 | 8 | 8 | 6 |
Serrated polyp not subclassified | 4 | 4 | 16 | 14 | 22 | 18 |
Hyperplastic polyp | 839 | 521 | 955 | 494 | 498 | 271 |
Total | 874 | 544 | 1111 | 565 | 607 | 329 |
↵*Diagnosis at baseline is determined by the local pathologist at each clinical centre. Postrandomisation polyps were all reviewed by the study pathologist.
↵†Includes all randomised subjects and lesions found within 1 year of randomisation.
↵‡Participants with more than one type of serrated polyp may be represented multiple times. Total is the number of subjects with any serrated polyp, counting each subject only once if they had multiple types of serrated polyps.
SSA/P, sessile serrated adenomas or polyp.